Clinique Pasteur Lanroze — Clinical Trial Site

36 Registered trials

18 Currently recruiting

Organisation

Clinique Pasteur Lanroze

Location

Brest, France

Identifier

ORG-100045599

Address

32 Rue Auguste Kervern, 29200, France

Departments

CFRO -Clinique Pasteur
Clinique Pasteur
Medical Oncology
Oncologie
Oncologie médicale
Oncologie Radiothérapie
Oncology
Oncology / Radiotheray
oncology department
Oncology-Radiotherapy
Radiation-oncologist
Radiology/Oncology
Radiothérapie
Radiotherapy
Radiotherapy Oncology
Service d'Oncologie médicale
Service Oncologie-Radiothérapie

Clinical trials at this site (36)

Search interface

LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy Pending

2024-515340-23-00 Colon cancer 4
ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with p… Pending

2024-517285-41-00 Newly diagnosed prostate cancer with pelvic lymph nodes 5
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Postmenopausal patients with small (pT1a-b pN0) hormone 4
Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m… Recruiting

2025-524408-30-01 Metastatic hormone-sensitive prostate cancer 5 2026-06-05
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5 2026-04-23
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Head and Neck Squamous Cell Carcinoma (HNSCC) 5 2024-10-15
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting

2024-519369-24-00 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER 5 2026-01-29
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting

2023-506817-23-01 Metastatic hormone naïve prostate cancer (mHNPC) 5 2025-05-23
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting

2024-510772-20-00 Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 4 2025-01-07
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting

2024-511070-68-01 Ampullary adenocarcinoma 5 2024-09-24
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren… Recruiting

2024-512999-35-00 Patients with HER 2 negative locally advanced, recurren 4 2023-06-23
Hyperthermic Intraperitoneal Chemotherapy in the treatment of Ovarian Cancer relapse Recruiting

2024-517390-24-00 Ovarian epithelial cancer : intraperitoneal resectable 5 2011-04-26
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended

2022-502369-10-00 Triple negative metastatic breast cancer 5 2023-10-02
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended

2024-514480-26-00 Post-menopausal women with localized luminal A breast c 4 2022-10-12